On Monday, researchers showed that the drug commonly used to maintain fluid in conditions such as hypertension, bomateanide, can alter Alzheimer’s symptoms in laboratory rats as well as in human brain cells. And through a study of the health records of millions of patients, the same researchers found that people over the age of 65 who regularly took bometinide were 35–75% less likely to be diagnosed with Alzheimer’s.
Facts and evidence Published in The age of nature, The gene revolves around APOE, which mediates fat metabolism in mammals but is also known to be a major risk factor for Alzheimer’s. By analyzing the APOE gene record in Alzheimer’s patients, with data from 1,300 existing medications, the researchers found that bometanide may be associated with altering the effects of the modified APOE gene. Drug mechanisms for altering fluid retention in cells also play a role in how neurons in the brain activate electrical signaling, so it seems to be able to detect.
It seems that the researchers’ insights on drugs were correct. And the ability of bometanide to treat Alzheimer’s is reinforced by the fact that it is already FDA-approved, and has a safety record that spans decades. Gladstone Institute researcher and study author Yadong Huang Said in a statement.
The good news is that clinical trials are beginning to test whether bumitanide can really help fight Alzheimer’s. Huang and his team are already in high-level talks with other medical centers to get it started.